Atracurium Besylate Injection
"The U.S. Food and Drug Administration today approved Clinolipid (lipid injectable emulsion, USP) for intravenous feeding (parenteral nutrition) in adult patients, providing a source of calories and essential fatty acids for adult patients who are"...
Atracurium Besylate Injection
Observed in Controlled Clinical Studies: Atracurium was well tolerated and produced few adverse reactions during extensive clinical trials. Most adverse reactions were suggestive of histamine release. In studies including 875 patients, atracurium was discontinued in only one patient (who required treatment for bronchial secretions) and six other patients required treatment for adverse reactions attributable to atracurium (wheezing in one, hypotension in five). Of the five patients who required treatment for hypotension, three had a history of significant cardiovascular disease. The overall incidence rate for clinically important adverse reactions, therefore, was 7/875 or 0.8%.
Table 1 includes all adverse reactions reported attributable to atracurium during clinical trials with 875 patients.
TABLE 1: PERCENT OF PATIENTS REPORTING ADVERSE REACTIONS Adverse Reaction Initial Atracurium Dose (mg/kg)
|0.00 - 0.30
(n = 485)
|0.31 - 0.50*
(n = 366)
| ≥ 0.60
(n = 24)
(n = 875)
|*Includes the recommended initial dosage range for most patients.|
Most adverse reactions were of little clinical significance unless they were associated with significant hemodynamic changes. Table 2 summarizes the incidences of substantial vital sign changes noted during atracurium clinical trials with 530 patients, without cardiovascular disease, in whom these parameters were assessed.
TABLE 2: PERCENT OF PATIENTS SHOWING > 30% VITAL SIGN CHANGES
FOLLOWING ADMINISTRATION OF ATRACURIUM
|Vital Sign Change||Initial
0.00 - 0.30
(n = 365)
0.31 - 0.50*
(n = 144)
(n = 21)
(n = 530)
|Mean Arterial Pressure|
*Includes the recommended initial dosage range for most patients.
Observed in Clinical Practice: Based on initial clinical practice experience in approximately 3 million patients who received atracurium in the U.S. and in the United Kingdom, spontaneously reported adverse reactions were uncommon (approximately 0.01% to 0.02%). The following adverse reactions are among the most frequently reported, but there are insufficient data to support an estimate of their incidence:
General: Allergic reactions (anaphylactic or anaphylactoid responses) which, in rare instances, were severe (e.g., cardiac arrest)
Musculoskeletal: Inadequate block, prolonged block
Respiratory: Dyspnea, bronchospasm, laryngospasm
There have been rare spontaneous reports of seizures in ICU patients following long-term infusion of atracurium to support mechanical ventilation. There are insufficient data to define the contribution, if any, of atracurium and/or its metabolite laudanosine. (See PRECAUTIONS: Long-Term Use in Intensive Care Unit [lCU]).
Read the Atracurium Besylate Injection (atracurium besylate injection) Side Effects Center for a complete guide to possible side effects
Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.
The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by atracurium besylate. Atracurium should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/20/2017
Additional Atracurium Besylate Injection Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.